Lv5
948 积分 2025-08-21 加入
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies
8天前
已完结
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib
10天前
已完结
A novel HER2-selective kinase inhibitor is effective in HER2 mutant and amplified non-small cell lung cancer
1个月前
已完结
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
1个月前
已完结
Monoclonal Antibodies Specific for Human IgE-Producing B Cells: A Potential Therapeutic for IgE-Mediated Allergic Diseases
3个月前
已完结
The pharmacological basis of anti-IgE therapy
3个月前
已完结
Humanization of an antibody directed against IgE
3个月前
已完结
Precision Oncology: 2025 in Review
3个月前
已完结
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
3个月前
已完结
Rubber Recycling: Challenges and Developments
6个月前
已采纳
Oral Health Psychology
6个月前
已采纳
The GLP-1 Receptor Agonist Dulaglutide Attenuates Hepatic Steatosis in Obesity via a Weight-Independent Mechanism
6个月前
已采纳
Framing Devices and Global Legal Traditions
7个月前
已采纳
Research Methods in Applied Linguistics (Oxford Applied Linguistics) by Zoltán Dörnyei (Author)
7个月前
已采纳
From Movements to Parties in Latin America
7个月前
已采纳
Science and Engineering of Freak Waves
7个月前
已采纳
The impact of ESG on corporate financial performance: Based on fixed effects regression model
7个月前
已采纳
Organizational Paradox
7个月前
已采纳
Methods of optimization
7个月前
已采纳
皖公网安备34019202002308
